Envestnet Asset Management Inc. Sells 75,401 Shares of Hologic, Inc. (NASDAQ:HOLX)

Envestnet Asset Management Inc. decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 18.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 339,284 shares of the medical equipment provider’s stock after selling 75,401 shares during the quarter. Envestnet Asset Management Inc. owned 0.15% of Hologic worth $24,459,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Resona Asset Management Co. Ltd. bought a new stake in Hologic during the fourth quarter worth about $6,090,000. Prudential PLC grew its position in Hologic by 4.5% during the 4th quarter. Prudential PLC now owns 87,841 shares of the medical equipment provider’s stock worth $6,332,000 after acquiring an additional 3,819 shares during the last quarter. Westpac Banking Corp increased its holdings in Hologic by 24.9% during the 4th quarter. Westpac Banking Corp now owns 41,173 shares of the medical equipment provider’s stock valued at $2,968,000 after purchasing an additional 8,200 shares in the last quarter. Bryce Point Capital LLC bought a new position in Hologic in the 4th quarter valued at $488,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Hologic by 56.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 44,291 shares of the medical equipment provider’s stock worth $3,193,000 after purchasing an additional 16,012 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HOLX. Raymond James reiterated an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Evercore ISI reduced their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Stephens reissued an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Shares of Hologic stock opened at $57.85 on Monday. Hologic, Inc. has a 12 month low of $56.27 and a 12 month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $12.98 billion, a PE ratio of 18.25, a PEG ratio of 2.14 and a beta of 0.82. The stock’s fifty day simple moving average is $62.47 and its 200 day simple moving average is $71.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.